The governance of Innovative Potential™ is equally dissipated throughout The Conglomeration and its Members. The Conglomeration Members are wholly independent of each other and are collaborationally-bound through recognition-of-function and mutually oriented goals to Innovative Potential™, and vice versa.

Innovative Potential was unified in March 2022 with a singular unifcation agreement cross-licensing all intellectual properties between Jordache Boudreau, Innovative Potential  Incorporated, and Innovative Potential Limited Liability Company, including the patents. The Exclusive Licensing Agreement (ELA) set forth the initial terms and rights of operation; function; ownership claim(s); defined ownership and property rights; and, defined and established a conflict resolution mechanism for Innovative Potential, the unified entity of Jordache Boudreau, Innovative Potential Incorporated, and Innovative Potential Limited Liability Company.

​​

NB: Innovative Potential, and Innovative Potential™, are legally referencing two (2) separate and distinct situational entities, respectively: a greater and broader set of ideas and concepts involved with the general case education and scenario, and: Innovative Potential as a legal  and or owned product. The language of this Website reflects this principle distinction from this point forwards with the presence or absence of the ™ designation.

​

Innovative Potential, through the ELA's statutes and mechanisms, then agreed to an initial Constitution made by combining the laws and constitutions of the United States of America and Canada, and adjusted for specific purpose and needs. Innovative Potential Constitutionally recognizes its entreatied and exclusivized rights to autonomously rule in contextual favor of curing cancer, or some other disease-curing greater good. The ideas and powers present are for Innovative Potential to be able to act freely in both patented nations using a common set of agreeable rules and laws for governing electrochemically activated chemotherapy (EAC) and the chemotherapeutic galvanostat/potentiostat (CGP) in all of its embodiments. The Constitution of Innovative Potential is continuing to define itself and evolve as conflicts, and new situations, are identified and are solved.

​

The Constitution of Innovative Potential also defines the purposes and requirements of the Conglomeration and its Members, collectively referred to as: The Conglomerati, in conceptual and physical relation to Innovative Potential and to each other (Figure 1). Innovative Potential's is a comprehensive Constitution governing extremely advanced biotechnological patent embodiments and surgical applications in multiple nations, across multiple health sciences disciplines, with several medical  applications, and contains the capacity for the exercising of autocratic powers for resolving conflicts at an individual level of resolution.

​

​​

​

​

​

​

​

​

​

​

​

​

​

​

​​

​Innovative Potential has an extremely definitive and exclusivizing Constitution that has implicitly, and entirely, incorporated the Constitution and laws of both Canada and the United States of America to be able to: improve the overall quality of life, and to: bring forth new surgical, pharmaceutical, and robotic biotechnologies.